Chemotherapy has long been a cornerstone in cancer treatment, with medications like fluorouracil (5-FU) and capecitabine (Xeloda or CAPE) playing a crucial role in combating the disease. However, recent studies have highlighted a genetic variant in the DPYD gene that can make these medications toxic or even fatal for a small percentage of patients. This genetic finding varies in different populations, with up to 8% of people carrying a variant that causes a partial deficiency of DPD, leading to increased exposure to the drugs’ toxic effects.
Patients with two variants in the DPYD gene, resulting in a complete absence of DPD function, face an even higher risk of severe side effects, including fatality. Recognizing and addressing toxicity promptly is essential, with an antidote called uridine triacetate available for immediate administration. However, this process must happen quickly to prevent serious consequences, underscoring the importance of early intervention and monitoring for potential adverse reactions.
In the UK and European Union, pre-treatment DPYD testing has been recommended since 2020 to identify patients at risk of adverse reactions to 5-FU and capecitabine. Genetic testing can help determine the appropriate dosage or alternative medications for individuals with DPYD variants, ultimately improving treatment outcomes and patient safety.
While the FDA in the United States recently issued warnings about the potential risks associated with DPYD deficiency, recommendations for genetic testing before prescribing these medications remain somewhat ambiguous. Despite the proven cost-effectiveness of genetic testing and its potential to prevent adverse events, only a small percentage of oncologists in the US currently order such testing for their patients.
Challenges in implementing genetic testing include the complexity of interpreting results, the rapid evolution of pharmacogenetic knowledge, and the lack of recognition and reimbursement for genetic counselors and pharmacists specializing in this area. Clinical decision support tools and guidelines can help clinicians navigate genetic testing and tailor treatment plans to individual patient needs, ensuring safer and more effective care.
As the field of pharmacogenetics continues to advance, efforts like the Right Drug Dose Now Act of 2024 aim to promote the integration of genetic testing into standard cancer care practices. Patients and healthcare providers are encouraged to discuss the potential benefits of genetic testing for medication response and consider its role in optimizing cancer treatment outcomes.
In conclusion, genetic testing offers a valuable tool in personalized cancer care, helping to identify patients at risk of adverse drug reactions and guiding treatment decisions. By incorporating genetic testing into standard practice, healthcare providers can enhance patient safety and treatment efficacy, ultimately improving outcomes for individuals undergoing chemotherapy.
